These compounds have demonstrated varying levels of c‐Myc inhibition against different cancer cell lines.1, 2, 3 With these structural insights in mind, we designed a series of novel c‐Myc inhibitors by incorporating 3,5‐bis(trifluoromethyl)benzene and thioxothiazolidinone ring moieties into their structures. Here, MYC is linked to cancer.